Publicaciones en colaboración con investigadores/as de Instituto de Química Médica (20)

2023

  1. Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity

    Nutrients, Vol. 15, Núm. 20

2021

  1. Palmitoleoylethanolamide is an efficient anti-obesity endogenous compound: Comparison with oleylethanolamide in diet-induced obesity

    Nutrients, Vol. 13, Núm. 8

2015

  1. Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation

    Journal of Medicinal Chemistry, Vol. 58, Núm. 16, pp. 6639-6652

2014

  1. CB1 blockade potentiates down-regulation of lipogenic gene expression in perirenal adipose tissue in high carbohydrate diet-induced obesity

    PLoS ONE, Vol. 9, Núm. 2

  2. Combining rimonabant and fentanyl in a single entity: Preparation and pharmacological results

    Drug Design, Development and Therapy, Vol. 8, pp. 263-277

2013

  1. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

  2. Ghrelin-Induced Orexigenic Effect in Rats Depends on the Metabolic Status and Is Counteracted by Peripheral CB1 Receptor Antagonism

    PLoS ONE, Vol. 8, Núm. 4

  3. Novel antiobesity agents: Synthesis and pharmacological evaluation of analogues of Rimonabant and of LH21

    Bioorganic and Medicinal Chemistry, Vol. 21, Núm. 7, pp. 1708-1716

2012

  1. Anti-obesity efficacy of LH-21, a cannabinoid CB 1 receptor antagonist with poor brain penetration, in diet-induced obese rats

    British Journal of Pharmacology, Vol. 165, Núm. 7, pp. 2274-2291

  2. Chromenopyrazoles: Non-psychoactive and Selective CB 1 Cannabinoid Agonists with Peripheral Antinociceptive Properties

    ChemMedChem, Vol. 7, Núm. 3, pp. 452-463

  3. Elaidyl-sulfamide, an oleoylethanolamide-modelled PPARα agonist, reduces body weight gain and plasma cholesterol in rats

    DMM Disease Models and Mechanisms, Vol. 5, Núm. 5, pp. 660-670

  4. Obesity and the Endocannabinoid System: Is There Still a Future for CB1 Antagonists in Obesity?

    Current Obesity Reports, Vol. 1, Núm. 4, pp. 216-228

2011

  1. Discovery of potent dual PPARα agonists/CB1 ligands

    ACS Medicinal Chemistry Letters, Vol. 2, Núm. 11, pp. 793-797

2010

  1. Synthesis and pharmacological evaluation of new (E)- and (Z)-3-aryl-4-styryl-1H-pyrazoles as potential cannabinoid ligands

    Arkivoc, Vol. 2010, Núm. 10, pp. 226-247

2009

  1. Synthesis and pharmacological evaluation of sulfamide-based analogues of anandamide

    European Journal of Medicinal Chemistry, Vol. 44, Núm. 12, pp. 4889-4895

2008

  1. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents

    Bioorganic and Medicinal Chemistry, Vol. 16, Núm. 23, pp. 10098-10105

  2. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats

    Journal of Neuroendocrinology

2007

  1. Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARα activation

    Journal of Medicinal Chemistry, Vol. 50, Núm. 2, pp. 389-393

2006

  1. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - LH 21

    Neuropharmacology, Vol. 51, Núm. 2, pp. 358-366

2004

  1. Discovery of 5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif

    Journal of Medicinal Chemistry, Vol. 47, Núm. 11, pp. 2939-2942